VolitionRx (NYSE MKT: VNRX) is a life sciences company
focused on developing simple to use, yet effective diagnostic tests for cancer
and other conditions by identifying and measuring nucleosomes in the
bloodstream or other bodily fluid – an indication that disease is present. In
recent months the company has made impressive strides toward its goal to bring
its diagnostic products to market by obtaining patent protection for its
technologies and leveraging invaluable personnel expertise.
VolitionRx today announced Dr. Jason Terrell, MD as its
full-time chief medical officer and head of U.S. operations. Dr. Terrell has
served in a part-time capacity in these roles since March 2013, and, on a
full-time basis, he will continue to lead and coordinate VolitionRx’s U.S.
operations in preparation for initial market entry of the company’s NuQ® blood
tests for cancer in the U.S. and worldwide.
“The recent results of clinical trials by VolitionRx have
been so compelling that we feel the time is right to employ a full-time head of
U.S. operations in preparation for introducing our NuQ® blood tests to the U.S.
market,” said Cameron Reynolds, president and chief executive officer of
VolitionRx. “In the past few months, we have secured U.S. patents to protect
our key technologies and are making strong progress toward our goal of
commercialization of NuQ® products. As a doctor holding medical licenses in 14
states across the U.S., Jason brings comprehensive experience and knowledge
regarding the U.S. regulatory environment and competitive situation, which
should be invaluable in developing VolitionRx’s strategy to enter the U.S.
market and gain FDA approval of our NuQ® cancer tests. In his role as
VolitionRx’s chief medical officer, Jason will continue to bring first-hand
insights of a medical practitioner and a deep understanding of patient
requirements.”
Through his part-time tenure with VolitionRx, Dr. Terell is
well-familiar with the potential of VolitionRx’s NuQ® tests and what they could
mean for oncology patients.
“In addition to now demonstrating more than 90% accuracy in
detecting colorectal, pancreatic and lung cancers, NuQ® tests are non-invasive for
patients, requiring only a single drop of blood, and are simple for doctors to
administer on existing clinical laboratory instruments,” said Dr. Terrell. “As
a doctor myself, it’s very exciting to be involved with bringing NuQ® tests to
market as they have the potential to make major advances in the early detection
of cancer, lead to a greater number of individuals being screened for various
cancers, and significantly improve patient outcomes.”
Dr. Terrell earned his medical degree at the University of
Texas and affiliate MD Anderson Cancer Center, with expertise in both clinical
medicine and the laboratory diagnostics business. He has a strong grounding in
diagnostics and product commercialization and has both executive and board
directorship experience with publicly traded companies in the biotechnology and
pharmaceutical industries. Dr. Terrell previously served on the board of
directors and as medical director for CDEX Inc., a company developing drug
validation technology. In addition, over the last six years, Dr. Terrell has
built and sold multiple private diagnostic laboratories and currently serves as
a National Franchise Corporate Medical Director for Any Lab Test Now, which
includes overseeing more than 70 franchises in 14 states.
Dr. Terrell earned a Bachelor of Science Biochemistry from
Hardin-Simmons University, where he graduated Summa Cum Laude, receiving the
Holland Medal of Honor as the top graduate in the School of Science and
Mathematics. He then attended the University of Texas at Houston Medical School
and affiliate MD Anderson Cancer Center to become Doctor of Medicine. He
undertook his General Medicine Internship, and Anatomic and Clinical Pathology
Residency at Texas Tech University Health Sciences Center. In February 2014,
Dr. Terrell was the recipient of the Outstanding Young Alumni Award from
Hardin-Simmons University.
For more information visit www.volitionrx.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
